Thoracic Research and Practice
Case report

Response of Complex Undefined Hypereosinophilic Syndrome to Treatment with Imatinib

1.

Department of Chest Diseases, Division of Immunology and Allergy, Erciyes University Faculty of Medicine, Kayseri, Turkey

2.

Department of Internal Medicine, Division of Hematology, Erciyes University Faculty of Medicine, Kayseri, Turkey

3.

Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Turkey

4.

Department of Pathology, Erciyes University Faculty of Medicine, Kayseri, Turkey

5.

Department of Radiology, Erciyes University Faculty of Medicine, Kayseri, Turkey

Thorac Res Pract 2016; 17: 118-121
DOI: 10.5578/ttj.30508
Read: 1692 Downloads: 1150 Published: 18 July 2019

Abstract

Hypereosinophilic syndomes (HESs) include potentially lethal multisystem disorders characterized by eosinophilic infiltration of a variable spectrum of target organs, predominantly the skin, heart, lungs, gastrointestinal tract, and nervous system. Based on recent advances in molecular and genetic diagnostic techniques and increasing experience with differences in clinical features and prognosis, subtypes have been defined, including "myeloproliferative-HES ", "lymphocytic-HES", "familial eosinophilia", "overlap HES", "undefined HES" ("complex undefined HES", "simple undefined HES", "episodic undefined HES") and "eosinophil associated diseases" (such as Churg-Strauss syndrome). HES should be kept in mind in the differential diagnosis of eosinophilic lung diseases especially in patients with peripheral eosinophilia and pulmonary infiltrates. Corticosteroids represent an effective firstline approach to decreasing eosinophil counts in the majority of cases. Imatinib might be used for corticosteroid nonresponders. We herein report a patient with "complex undefined HES" who had disease resistant to corticosteroids, but who had a significant response after treatment with imatinib.

Files
EISSN 2979-9139